OncoMatch/Clinical Trials/NCT05806060
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Is NCT05806060 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including VEGFR and TPC and TPC for triple-negative breast cancer.
Treatment: VEGFR and TPC · TPC — The study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune suppressed (BLIS) subtype of triple-negative breast cancer (TNBC) in the first-line teatment of unresectable locally advanced or metastatic TNBC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) absence of expression
absence of HER2, ER, and PR expression
Required: ESR1 absence of expression
absence of HER2, ER, and PR expression
Required: PR (PGR) absence of expression
absence of HER2, ER, and PR expression
Disease stage
Required: Stage IV
Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: no previous chemotherapy for metastatic triple-negative breast cancer
Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer
Cannot have received: targeted therapy
Exception: no previous targeted therapy for metastatic triple-negative breast cancer
Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer
Lab requirements
Blood counts
The functions of major organs are basically normal
Kidney function
The functions of major organs are basically normal; Urine protein ≥2+ and 24h urine protein quantitative > 1.0 g [excluded]
Liver function
The functions of major organs are basically normal; Patients with known active HBV or HCV infection or hepatitis B DNA≥500, or chronic phase with abnormal liver function [excluded]
Cardiac function
Significant cardiovascular disease [excluded]
The functions of major organs are basically normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05806060 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 absence of expression is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 absence of expression is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR absence of expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify